Patient characteristics
| Patient characteristics . | Disease characteristics . | Treatment (at enrollment) . | Hematologic parameters (at enrollment/at diagnosis) . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | Sex . | Age at enrollment (mo) . | Tumor type . | Tumor site . | Age at diagnosis (mo) . | Platelet (×109/L) . | Hb (g/L) . | Fibrinogen (g/L) . | D-dimer (ng/L) . | TB (μmol/L) . | DB (μmol/L) . | |
| 1 (D.)∗ | M | 3 | KHE | Soft tissue of the head and neck | 0 | LD (30 mg/m2), vinblastine (1 mg/m2), cyclophosphamide (50 mg/m2) | 54/5 | 88/75 | 2.6/1.3 | ND | 7.1/177.6 | 3.1/2.3 |
| 2 (K.) | F | 7 | KHE (CD34+, CD31+, PDPN+) | Soft tissue of the head | 0 | LD (30 mg/m2), vinblastine (1 mg/m2), cyclophosphamide (50 mg/m2) | 238/13 | 100/101 | 4.4/1.5 | 487/5325 | 3.3/7.1 | 1.4/2.2 |
| 3 (M.) | M | 17 | KHE | Soft tissue of the forearm | 0 | Sirolimus (1.6 mg/m2), prednisolone (5 mg/kg daily) | 294/36 | 111 /86 | 4.0/1.0 | 158/1619 | 5.7/4.9 | 2.6/1.8 |
| 4 (A.) | M | 11 | KHE (CD34+, CD31+, PDPN+) | Soft tissue of the upper back, thorax | 3 | vinblastine (1 mg/m2), cyclophosphamide (50 mg/m2) | 252/41 | 102/95 | 2.2/1.2 | 117/5423 | 8.2/8.8 | 3.8/3.1 |
| 5 (P.) | M | 7 | KHE (CD34+, CD31+, PDPN+, factor VIII+) | Soft tissue of the left axilla | 0 | LD (30 mg/m2), vinblastine (1 mg/m2), cyclophosphamide (50 mg/m2) | 380/78 | 111/74 | 2.1/1.0 | 138/6697 | 5.4/11.1 | 2.3/8.5 |
| 6 (F.) | M | 18 | Kaposiform lymphangiomatosis (CD34+, CD31+, PDPN+, CD61+) | Soft tissue of neck, upper chest; mediastinum | 13 | LD (30 mg//m2), sirolimus (0.5 mg x 2 daily) | 209/22 | 114/61 | 3.5/2.0 | 156/1069 | 2.1/6.2 | 1.3/0.7 |
| 7 (V.) | F | 36 | KHE (CD34+, CD31+, PDPN+, CD61+, factor VIII+) | Soft tissue of the neck, upper back and chest | 0 | LD (30 mg/m2), vincristine (1.5 mg/m2), atenolol (12.5 mg x 1 daily) | 293/110 | 98/80 | 3.2/0.3 | 718/7412 | 4.7/465.3 | 2.1/15.5 |
| 8 (B.) | F | 1 | KHE | Soft tissue of the right leg, perineum | 0 | prednisolone (2mg/kg daily), propranolol (2 mg/kg daily) | 6/4 | 77/72 | 0.9/0.3 | 5184/9412 | 5.1/7.3 | 4.1/5.5 |
| 9 (Pe.) | M | 5 | KHE | Soft tissue of the thorax | 3.5 | propranolol (0.6 mg/kg daily), LD (30 mg/m2), vinblastine (0.33 mg/m2), cyclophosphamide (50 mg/m2) | 10/3 | 107/75 | 1.0/0.3 | 23 042/52 722 | ND/ND | 1.8/4.1 |
| 10 (G.) | M | 2.5 | Rapidly involuting congenital hemangioma | Soft tissue of the forearm | 2.5 | propranolol (2.5 mg/kg daily) | 126/16 | 97/81 | 1.6/0.9 | 6223/ND | 17.2/328 | 6.2/15.5 |
| 11 (Ki.) | M | 3 | KHE | Soft tissue of the thorax | 3 | propranolol (3.5 mg/kg daily) | 6/6 | 108/88 | 0.8/0.8 | 16 542/16 542 | 8.7/8.7 | ND/ND |
| 12 (Ch.) | F | 3 | KHE | Soft tissue of the thorax | 2.5 | prednisolone (5 mg/kg daily), propranolol (2 mg/kg daily) | 49/10 | 92/75 | 0.2/0.2 | 9835/9835 | ND/ND | 2.8/ND |
| 13 (Ty.) | F | 12 | KHE | Soft tissue of the forearm | 6 | LD (5 mg/m2), vinblastine (1 mg), cyclophosphamide (50 mg/m2) | 295/71 | 107/95 | 2.03/0.2 | 239/8503 | 7.9/8.1 | 2.9/3 |
| Patient characteristics . | Disease characteristics . | Treatment (at enrollment) . | Hematologic parameters (at enrollment/at diagnosis) . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | Sex . | Age at enrollment (mo) . | Tumor type . | Tumor site . | Age at diagnosis (mo) . | Platelet (×109/L) . | Hb (g/L) . | Fibrinogen (g/L) . | D-dimer (ng/L) . | TB (μmol/L) . | DB (μmol/L) . | |
| 1 (D.)∗ | M | 3 | KHE | Soft tissue of the head and neck | 0 | LD (30 mg/m2), vinblastine (1 mg/m2), cyclophosphamide (50 mg/m2) | 54/5 | 88/75 | 2.6/1.3 | ND | 7.1/177.6 | 3.1/2.3 |
| 2 (K.) | F | 7 | KHE (CD34+, CD31+, PDPN+) | Soft tissue of the head | 0 | LD (30 mg/m2), vinblastine (1 mg/m2), cyclophosphamide (50 mg/m2) | 238/13 | 100/101 | 4.4/1.5 | 487/5325 | 3.3/7.1 | 1.4/2.2 |
| 3 (M.) | M | 17 | KHE | Soft tissue of the forearm | 0 | Sirolimus (1.6 mg/m2), prednisolone (5 mg/kg daily) | 294/36 | 111 /86 | 4.0/1.0 | 158/1619 | 5.7/4.9 | 2.6/1.8 |
| 4 (A.) | M | 11 | KHE (CD34+, CD31+, PDPN+) | Soft tissue of the upper back, thorax | 3 | vinblastine (1 mg/m2), cyclophosphamide (50 mg/m2) | 252/41 | 102/95 | 2.2/1.2 | 117/5423 | 8.2/8.8 | 3.8/3.1 |
| 5 (P.) | M | 7 | KHE (CD34+, CD31+, PDPN+, factor VIII+) | Soft tissue of the left axilla | 0 | LD (30 mg/m2), vinblastine (1 mg/m2), cyclophosphamide (50 mg/m2) | 380/78 | 111/74 | 2.1/1.0 | 138/6697 | 5.4/11.1 | 2.3/8.5 |
| 6 (F.) | M | 18 | Kaposiform lymphangiomatosis (CD34+, CD31+, PDPN+, CD61+) | Soft tissue of neck, upper chest; mediastinum | 13 | LD (30 mg//m2), sirolimus (0.5 mg x 2 daily) | 209/22 | 114/61 | 3.5/2.0 | 156/1069 | 2.1/6.2 | 1.3/0.7 |
| 7 (V.) | F | 36 | KHE (CD34+, CD31+, PDPN+, CD61+, factor VIII+) | Soft tissue of the neck, upper back and chest | 0 | LD (30 mg/m2), vincristine (1.5 mg/m2), atenolol (12.5 mg x 1 daily) | 293/110 | 98/80 | 3.2/0.3 | 718/7412 | 4.7/465.3 | 2.1/15.5 |
| 8 (B.) | F | 1 | KHE | Soft tissue of the right leg, perineum | 0 | prednisolone (2mg/kg daily), propranolol (2 mg/kg daily) | 6/4 | 77/72 | 0.9/0.3 | 5184/9412 | 5.1/7.3 | 4.1/5.5 |
| 9 (Pe.) | M | 5 | KHE | Soft tissue of the thorax | 3.5 | propranolol (0.6 mg/kg daily), LD (30 mg/m2), vinblastine (0.33 mg/m2), cyclophosphamide (50 mg/m2) | 10/3 | 107/75 | 1.0/0.3 | 23 042/52 722 | ND/ND | 1.8/4.1 |
| 10 (G.) | M | 2.5 | Rapidly involuting congenital hemangioma | Soft tissue of the forearm | 2.5 | propranolol (2.5 mg/kg daily) | 126/16 | 97/81 | 1.6/0.9 | 6223/ND | 17.2/328 | 6.2/15.5 |
| 11 (Ki.) | M | 3 | KHE | Soft tissue of the thorax | 3 | propranolol (3.5 mg/kg daily) | 6/6 | 108/88 | 0.8/0.8 | 16 542/16 542 | 8.7/8.7 | ND/ND |
| 12 (Ch.) | F | 3 | KHE | Soft tissue of the thorax | 2.5 | prednisolone (5 mg/kg daily), propranolol (2 mg/kg daily) | 49/10 | 92/75 | 0.2/0.2 | 9835/9835 | ND/ND | 2.8/ND |
| 13 (Ty.) | F | 12 | KHE | Soft tissue of the forearm | 6 | LD (5 mg/m2), vinblastine (1 mg), cyclophosphamide (50 mg/m2) | 295/71 | 107/95 | 2.03/0.2 | 239/8503 | 7.9/8.1 | 2.9/3 |
ALT, alanine aminotransferase; DB, direct bilirubin; Hb, hemoglobin, ND, no data; PDPN, podoplanin; PLT, platelet count.
The capital letters have been introduced to distinguish patients and do not reflect their personal information.